BioStock: Miris reporting record sales

The year-end report for 2022 shows a record for Miris' sales of analysis instruments that promote neonatal health. With a sales increase of 22 percent and gross margins of 75 percent, the medical technology company is well on its way to establishing Miris HMA as standard care for breast milk analysis. BioStock contacted CEO Camilla Myhre Sandberg to learn more about sales records, market potential and the outlook going forward.

Read the interview with Miris' CEO Camilla Myhre Sandberg at biostock.se:

https://www.biostock.se/en/2023/03/miris-reporting-record-sales/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se